Haemate

Haemate is a prescription‑only hemostatic agent that contains human coagulation factor VIII and human von Willebrand factor. It is supplied as an injectable solution for intravenous administration; the specific strength is not publicly disclosed. The product is manufactured for the European market and is used to replace deficient clotting proteins in patients with hemophilia A or von Willebrand disease, supporting normal blood clot formation effectively and physiologically.

Haemate is indicated for the management of bleeding disorders that involve a deficiency of factor VIII and von Willebrand factor.

- Treatment of acute bleeding episodes in patients with hemophilia A. - Perioperative prophylaxis to prevent surgical bleeding in hemophilia A. - Management of mucosal or gastrointestinal bleeding in von Willebrand disease. - Long‑term prophylactic therapy to reduce the frequency of spontaneous bleeds in severe hemophilia A. - Replacement therapy for patients with combined factor VIII and von Willebrand factor deficiency.

Adverse reactions reported with Haemate vary in frequency and severity; they are categorized as common or serious.

Common: - Mild headache or fatigue. - Transient fever, chills, or rigors. - Local infusion site reactions such as erythema, swelling, or pain. - Nausea or vomiting.

Serious: - Development of inhibitors (antibodies) against factor VIII. - Anaphylactic or severe allergic reactions, including urticaria. - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. - Renal impairment or hemolysis.

Before initiating Haemate therapy, clinicians should evaluate patient history and monitor specific parameters to minimize risk.

- Assess for prior inhibitors to factor VIII or allergic reactions to plasma‑derived products. - Perform baseline coagulation studies and periodic factor activity levels during treatment. - Use caution in patients with a history of thrombosis or cardiovascular disease. - Monitor for signs of infection, especially viral transmission, as the product is derived from human plasma. - Adjust dosing in patients with renal or hepatic impairment as recommended by clinical guidelines. - Educate patients on proper infusion techniques and the importance of reporting adverse symptoms promptly.

Haemate may interact with other medications that affect hemostasis or immune response; awareness of these interactions helps ensure safe use.

Avoid: - Concomitant use of other factor concentrates or bypassing agents without specialist guidance. - Administration of pro‑thrombotic agents such as activated protein C or high‑dose estrogen therapy.

Use with caution: - Antifibrinolytic agents (e.g., tranexamic acid) may augment hemostatic effect and require dose adjustment. - Immunosuppressive drugs can alter inhibitor development risk and should be monitored. - Vaccinations, particularly live vaccines, should be timed appropriately around infusion sessions. - Renal‑clearing medications such as aminoglycosides may affect drug clearance and need monitoring.